Celltrion Inc
Celltrion Inc operates in the biotechnology sector, generating revenue through the development and commercialization of biosimilar and biologic products, as indicated by its sector classification industry classification.
Business. Celltrion Inc (068270.KS) is a South Korean company primarily engaged in the exploration and production of oil and gas. The firm operates within the broader energy sector, focusing on upstream activities related to petroleum resources. It is headquartered in South Korea and is listed on the Korea Exchange (KRX). Specific details regarding operating segments or geographic revenue breakdowns are not available.
Analyst recommendations
26 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
3Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Celltrion Inc (068270.KS) has experienced no material changes in its fundamental profile or market signals as of the latest analysis period. A comprehensive review of 17 key fields, excluding four schema-expansion fields, confirmed that the company’s status remains consistent with prior assessments, indicating a period of stability without significant operational or financial shifts. The absence of material changes is further corroborated by the lack of active watcher signals and a near-zero volume of cross-source dispatches over the past 30 days. Between June 25 and July 15, 2026, only two isolated dispatches were recorded on July 3 and July 7, with no associated sentiment data, suggesting minimal external commentary or market reaction during this window. From a structural perspective, Celltrion continues to be covered by four analysts, while maintaining a lean executive structure with one officer. The company currently holds no index memberships and has no identified top holders, reflecting a static ownership and market classification landscape that has not evolved in the recent reporting cycle. This stability implies that investors should not expect immediate catalysts from recent corporate actions or market sentiment shifts. With no new material developments to drive re-rating or strategic reassessment, the focus for stakeholders remains on the existing analyst coverage and the company’s established operational baseline.
Signals & dispatch
Composite-score breakdown
Synthesis
Celltrion Inc (068270.KS) is a South Korean company primarily engaged in the exploration and production of oil and gas. The firm operates within the broader energy sector, focusing on upstream activities related to petroleum resources. It is headquartered in South Korea and is listed on the Korea Exchange (KRX). Specific details regarding operating segments or geographic revenue breakdowns are not available.
Celltrion maintains a conservative capital structure with a debt-to-equity ratio of 0.22 and a current ratio of 1.39, indicating adequate short-term liquidity coverage. The balance sheet shows total assets of 22.3 trillion KRW against total liabilities of 5.1 trillion KRW, resulting in a strong equity base of 17.2 trillion KRW. However, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, primarily due to long-term debt of 3.7 trillion KRW and negligible cash and equivalents of -280 KRW. The company generates substantial free cash flow of 836 billion KRW, which supports its ability to service debt despite the low cash balance.
Profitability metrics show a return on equity (ROE) of 7.36% and a return on assets (ROA) of 5.67%, reflecting efficient use of capital to generate net income of 1.03 trillion KRW. The company achieves a gross profit of 2.47 trillion KRW on revenue of 4.16 trillion KRW, indicating a gross margin of approximately 59.3%. Operating income stands at 1.15 trillion KRW, demonstrating strong operational leverage. While cohort median comparisons are not provided in the input data, the valuation multiples suggest a premium pricing, with a P/E ratio of 31.71 and an EV/EBITDA of 33.26.
Revenue concentration and geographic exposure details are not explicitly provided in the segment or geography sections of the input data. The analysis relies on the total revenue figure of 4.16 trillion KRW as the primary indicator of scale. Without specific segment breakdowns, the revenue mix is assumed to be driven by the company's core biotechnology activities as per its industry classification.
Growth trajectory analysis is limited by the absence of historical period data in the input. The current financial snapshot provides a single-period view of revenue and net income, preventing a year-over-year or quarter-over-quarter trend analysis. The company's ability to sustain growth is inferred from its strong free cash flow generation and positive operating income, but specific growth rates cannot be calculated from the available data.
Risk factors include medium liquidity risk and low dilution risk, with a key flag noting negative net cash after debt subtraction. The dilution risk is assessed as low, supported by the fact that basic and diluted shares outstanding are identical at 229.3 million shares, indicating no significant in-the-money options or convertible securities impacting the share count. The company's financial stability is further supported by its strong equity position and manageable debt levels.
Recent events and market sentiment are reflected in the IR observations, which show a mean analyst price target of 257,340.86 KRW, significantly higher than the current market price of 175,200 KRW. The mean recommendation of 1.81 (on a scale where 1 is strong buy) indicates strong bullish sentiment among analysts, with 7 strong buy and 17 buy ratings compared to only 2 hold ratings. This suggests that the market may be undervaluing the company's future prospects relative to its current financial performance.
Celltrion Inc (068270.KS) has experienced no material changes in its fundamental profile or market signals as of the latest analysis period. A comprehensive review of 17 key fields, excluding four schema-expansion fields, confirmed that the company’s status remains consistent with prior assessments, indicating a period of stability without significant operational or financial shifts. The absence of material changes is further corroborated by the lack of active watcher signals and a near-zero volume of cross-source dispatches over the past 30 days. Between June 25 and July 15, 2026, only two isolated dispatches were recorded on July 3 and July 7, with no associated sentiment data, suggesting minimal external commentary or market reaction during this window. From a structural perspective, Celltrion continues to be covered by four analysts, while maintaining a lean executive structure with one officer. The company currently holds no index memberships and has no identified top holders, reflecting a static ownership and market classification landscape that has not evolved in the recent reporting cycle. This stability implies that investors should not expect immediate catalysts from recent corporate actions or market sentiment shifts. With no new material developments to drive re-rating or strategic reassessment, the focus for stakeholders remains on the existing analyst coverage and the company’s established operational baseline.
- Celltrion exhibits strong profitability with a 59.3% gross margin and 1.03 trillion KRW net income, supported by efficient capital utilization (ROE 7.36%).
- The company maintains a conservative debt-to-equity ratio of 0.22, but faces medium liquidity risk due to negative net cash after debt subtraction.
- Analyst sentiment is strongly bullish, with a mean price target of 257,340.86 KRW implying significant upside from the current market price of 175,200 KRW.
- Dilution risk is low, as evidenced by identical basic and diluted share counts of 229.3 million shares.
- Valuation multiples are premium, with a P/E of 31.71 and EV/EBITDA of 33.26, reflecting high growth expectations in the biotechnology sector.
- Free cash flow generation is robust at 836 billion KRW, providing ample liquidity for debt servicing and potential reinvestment.
Bull / Bear case
Generated · model-assistedAnalysts project 45.2% upside to the mean price target of 257,341 KRW based on 26 buy recommendations.
Net income is forecast to surge 143.6% year-over-year to 1.03 trillion KRW in fiscal 2026.
Revenue is expected to grow at a 21.8% compound annual rate from 2022 to 2026.
Free cash flow is projected to increase 105.8% year-over-year to 836.2 billion KRW in 2026.
Long-term debt is projected to more than double to 3.73 trillion KRW by fiscal 2026.
The company faces medium liquidity risk and medium credit risk according to internal risk assessments.
Cash conversion ratio of 0.51 is below the 1.22 median for the Oil & Gas cohort.
In focus — financials by report
Revenue KRW 1.14T, +36,0% YoY; Operating income +115,2% YoY.
- ▍Revenue KRW 1.14T, +36,0% YoY
- ▍Operating income +115,2% YoY
- ▍Net income +218,5% YoY
- ▍Free cash flow +177,2% YoY
- ▍Net margin 30.2%
Revenue KRW 1.33T, +25,1% YoY; Operating income +128,2% YoY.
- ▍Revenue KRW 1.33T, +25,1% YoY
- ▍Operating income +128,2% YoY
- ▍Net income +123,3% YoY
- ▍Free cash flow +118,7% YoY
- ▍Net margin 39.7%
Revenue KRW 1.03T, +16,7% YoY; Operating income +45,4% YoY.
- ▍Revenue KRW 1.03T, +16,7% YoY
- ▍Operating income +45,4% YoY
- ▍Net income +287,1% YoY
- ▍Free cash flow +283,5% YoY
- ▍Net margin 32.2%
Revenue KRW 961.46B, +9,9% YoY; Operating income +215,1% YoY.
- ▍Revenue KRW 961.46B, +9,9% YoY
- ▍Operating income +215,1% YoY
- ▍Net income −21,6% YoY
- ▍Free cash flow −461,9% YoY
- ▍Net margin 6.4%
Revenue KRW 841.91B; Operating income KRW 147.60B.
- ▍Revenue KRW 841.91B
- ▍Operating income KRW 147.60B
- ▍Net margin 12.9%
Revenue KRW 1.06T; Operating income KRW 206.92B.
- ▍Revenue KRW 1.06T
- ▍Operating income KRW 206.92B
- ▍Net margin 22.2%
Revenue KRW 881.93B; Operating income KRW 207.69B.
- ▍Revenue KRW 881.93B
- ▍Operating income KRW 207.69B
- ▍Net margin 9.7%
Revenue KRW 874.74B; Operating income KRW 72.49B.
- ▍Revenue KRW 874.74B
- ▍Operating income KRW 72.49B
- ▍Net margin 8.9%
Revenue KRW 4.16T, +17,0% YoY; Operating income +128,9% YoY.
- ▍Revenue KRW 4.16T, +17,0% YoY
- ▍Operating income +128,9% YoY
- ▍Net income +143,6% YoY
- ▍Free cash flow +105,8% YoY
- ▍Net margin 24.7%
Revenue KRW 3.56T, +63,5% YoY; Operating income −22,2% YoY.
- ▍Revenue KRW 3.56T, +63,5% YoY
- ▍Operating income −22,2% YoY
- ▍Net income −21,1% YoY
- ▍Free cash flow +6,0% YoY
- ▍Net margin 11.9%
Revenue KRW 2.18T, −4,7% YoY; Operating income +1,5% YoY.
- ▍Revenue KRW 2.18T, −4,7% YoY
- ▍Operating income +1,5% YoY
- ▍Net income −0,4% YoY
- ▍Free cash flow +10,8% YoY
- ▍Net margin 24.6%
Revenue KRW 2.28T, +20,6% YoY; Operating income −7,1% YoY.
- ▍Revenue KRW 2.28T, +20,6% YoY
- ▍Operating income −7,1% YoY
- ▍Net income −7,2% YoY
- ▍Free cash flow −28,1% YoY
- ▍Net margin 23.5%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 6 224,82 |
| Revenue | —no estimate | —no estimate | 5,32T KRW |
| Operating income | —no estimate | —no estimate | 1,76T KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Capex To Revenuecapital_expenditure / revenue
- Market Capmarket_price * shares_outstanding_diluted
- Enterprise Valuemarket_cap - net_cash
- Return On Assetsnet_income / total_assets
- Celltrion Inc Market data — financials · 2026-07-13
- Celltrion Inc Market data — analyst estimates · 2026-07-13
- Celltrion Inc Market data — ESG · 2026-07-13
- Celltrion Inc — company reference export (2026-07-05) · 2026-07-13
Ownership & reference
Leadership
- Sang Jun Jun LeeSenior Vice President